Cogent Biosciences to Present at Ladenburg Thalmann Virtual Healthcare Conference 2021

Rhea-AI Summary

Cogent Biosciences, Inc. (Nasdaq: COGT) announced that CEO Andrew Robbins will present at the Ladenburg Thalmann Virtual Healthcare Conference on July 14, 2021, from 2:00-2:25 pm ET. The event will highlight the company's focus on developing precision therapies for genetically defined diseases, including the clinical program for bezuclastinib, targeting the KIT D816V mutation linked to systemic mastocytosis and gastrointestinal stromal tumors. Interested parties can access the live webcast and archived recording through the Cogent Biosciences investor relations website.

News Market Reaction – COGT

+0.38%

+0.38% Session move

In the trading session that priced this news, COGT gained 0.38%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass. and BOULDER, Colo., June 29, 2021 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins, Chief Executive Officer and President, will present at the Ladenburg Thalmann Virtual Healthcare Conference on Wednesday, July 14^th, from 2:00-2:25pm ET.

Access to the webcast of this event, as well as an archived recording, will be available under the "Events" tab on the investor relations section of the Cogent Biosciences website at: https://investors.cogentbio.com/events.

About Cogent Biosciences, Inc. 
Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. In addition to bezuclastinib, the newly formed Cogent Research team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases. Cogent Biosciences is based in Cambridge, MA and Boulder, Co. Visit our website for more information at www.cogentbio.com. Follow Cogent Biosciences on social media: Twitter and LinkedIn. Information that may be important to investors will be routinely posted on our website and Twitter.

View original content to download multimedia:https://www.prnewswire.com/news-releases/cogent-biosciences-to-present-at-ladenburg-thalmann-virtual-healthcare-conference-2021-301321235.html

SOURCE Cogent Biosciences, Inc.

FAQ

When will Cogent Biosciences present at the Ladenburg Thalmann Virtual Healthcare Conference?

Cogent Biosciences will present on July 14, 2021, from 2:00-2:25 pm ET.

Who is presenting at the Ladenburg Thalmann Virtual Healthcare Conference for COGT?

Andrew Robbins, the CEO, will be presenting at the conference.

What is the main focus of Cogent Biosciences?

Cogent Biosciences focuses on developing precision therapies for genetically defined diseases.

What is bezuclastinib?

Bezuclastinib is a selective tyrosine kinase inhibitor designed to target the KIT D816V mutation.

Where can I access the webcast for Cogent Biosciences' presentation?

The webcast will be available on the Cogent Biosciences investor relations website under the Events tab.